Jasper Therapeutics
JSPR
57 hedge funds and large institutions have $82.2M invested in Jasper Therapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
8% more funds holding
Funds holding: 53 → 57 (+4)
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
1% less capital invested
Capital invested by funds: $82.7M → $82.2M (-$520K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$4.35M |
| 2 |
MSU
Mizuho Securities USA
New York
|
+$3.93M |
| 3 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
+$3.25M |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.99M |
| 5 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$9.84M |
| 2 |
SRCM
Sage Rock Capital Management
New York
|
-$4.59M |
| 3 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$2.73M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.09M |
| 5 |
LA
Linden Advisors
New York
|
-$1.27M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
51
Panagora Asset Management
Boston,
Massachusetts
| $45K | -$29.3K | -295 | -40% |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| $21K | -$22.1K | -222 | -52% |
|
53
UBS Group
Zurich,
Switzerland
| $18K | +$4.37K | +44 | +33% |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
AA
55
Ancora Advisors
Cleveland,
Ohio
| $1K | +$994 | +10 | New |
|
56
Walleye Capital
New York
| $867 | +$116K | +1,170 | +15% |
|
|
MF
57
Magnetar Financial
Evanston,
Illinois
| $381 | +$380K | +3,825 | New |
|
|
SRCM
58
Sage Rock Capital Management
New York
| – | -$4.59M | -46,356 | Closed |
|
|
LA
59
Linden Advisors
New York
| – | -$1.27M | -12,769 | Closed |
|
|
CC
60
Centiva Capital
New York
| – | -$298K | -3,000 | Closed |
|
|
OAC
61
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$225K | -2,260 | Closed |
|
|
VCM
62
Vivaldi Capital Management
Chicago,
Illinois
| – | -$150K | -1,512 | Closed |
|
JSPR Hedge Fund Activity: Q2 2021 in Review
57 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2021, worth a combined $82.2M — down 0.63% from $82.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new JSPR positions and 5 closed out — a net gain of 4 holders — while 14 added to existing stakes and 14 trimmed.
The largest buyer was W.R. Berkley Corp, opening a new position worth an estimated $4.35M. The largest seller was Glazer Capital LLC, cutting an estimated $9.84M.
- 57 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2021, up from 53 in Q1 2021.
- Funds reported $82.2M of Jasper Therapeutics stock for Q2 2021, down 0.63% quarter-over-quarter.
- 9 funds opened new Jasper Therapeutics positions in Q2 2021 and 5 closed out, a net change of +4 holders.
- The largest Jasper Therapeutics buyer in Q2 2021 was W.R. Berkley Corp, an estimated $4.35M added.
- The largest Jasper Therapeutics seller in Q2 2021 was Glazer Capital LLC, an estimated $9.84M sold.
Based on aggregated 13F filings for Q2 2021.